K

Kyowa Kirin

Global specialty pharma focused on antibodies

Principal Chemistry, Manufacturing, and Controls Regulatory Affairs

Full-TimeUpdated on 10/23/2026
$140k - $175k+ Annual Bonus Program + 401(k) Match + Long-Term Incentive Program
Senior, Expert
Bachelor's, Master's, PharmD, PhD
Sanford, NC, USA
In Person100% on-site in Sanford, NC; requires up to 10% domestic and international travel.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor's degree in a relevant scientific discipline, such as Pharmacy, Pharmaceutical Sciences, Chemistry, Biochemistry, Chemical Engineering, or a closely related field; an advanced degree (M.S., Pharm.D., Ph.D., or equivalent) is preferred, particularly in a pharmaceutical, scientific, or regulatory discipline.
  • At least eight years of progressive regulatory affairs experience in the biotechnology, pharmaceutical, or life sciences industry, with substantial focus on CMC regulatory affairs.
  • A proven track record supporting U.S. BLA post-approval activities and lifecycle management.
  • Demonstrated success managing complex regulatory CMC activities and projects across site, technical, quality, manufacturing, and global regulatory functions.
  • Prior involvement in FDA interactions and health authority engagements, including preparing regulatory materials, responding to agency questions, and completing follow-up activities.
  • Background in manufacturing site regulatory activities, including technology transfers, manufacturing changes, facility readiness, and evaluation of regulatory impact.
  • Demonstrated application of regulatory strategy and sound judgment to identify risks, evaluate options, and develop practical approaches to complex CMC issues.
  • A track record of working effectively within a matrixed organization and influencing outcomes across site-based and global functions without direct authority.
  • In-depth knowledge of U.S. FDA biopharmaceutical CMC regulatory requirements, including requirements for development, manufacturing, post-approval changes, technology transfer, and lifecycle management.
  • Strong understanding of the FDA PreCheck Pilot Program and its regulatory framework, including early FDA engagement, facility information, Type V DMFs, pre-operational reviews, facility readiness, and subsequent application and inspection activities.
  • Proficiency in CMC regulatory submissions and documentation, including BLA-related CMC content, post-approval supplements, Type V DMFs, regulatory responses, and supporting technical documentation.
  • Regulatory strategy and analytical capabilities to evaluate CMC regulatory risks, interpret complex technical information, and develop practical, risk-based recommendations.
  • Advanced regulatory writing and presentation capabilities to communicate complex scientific and regulatory concepts clearly to technical, site, senior leadership, and health authority audiences.
  • Cross-functional communication and stakeholder management skills to build alignment, influence decision-making, and communicate regulatory strategy and risk across site and global functions.
  • Proficiency with Microsoft Office Suite, including Word, Excel, PowerPoint, and Outlook.
  • Ability to organize and prioritize work, meet deadlines, make decisions, and change course quickly; strong work ethic, attention to detail, and follow-through; ability to work with ambiguity in a dynamic, fast-paced environment; and cultural sensitivity to develop consensus within a multinational organization.
Responsibilities
  • Serve as the primary GRA-CMC interface for the Sanford site, providing regulatory CMC leadership, strategic guidance, and oversight to align site activities with global regulatory strategies, applicable requirements, and company standards.
  • Direct GRA-CMC activities associated with the FDA PreCheck program, including preparing for FDA interactions, regulatory communications, responses to agency requests, and follow-up activities.
  • Own the preparation, submission, and lifecycle management of the Sanford Type V DMF, keeping its content accurate, current, and aligned with applicable regulatory requirements and product development and manufacturing activities.
  • Represent GRA-CMC in Sanford technology transfer activities, ensuring regulatory requirements, filing considerations, and regulatory commitments are identified early and incorporated into technical strategies and execution plans.
  • Assess regulatory CMC implications of Sanford site changes and manufacturing activities, including facility readiness, process and equipment changes, technical initiatives, and other activities with potential regulatory impact.
  • Partner with Sanford Quality, Manufacturing, MSAT, Supply Chain, other technical functions, global GRA-CMC, and development teams to identify, assess, and resolve regulatory CMC matters in a timely manner.
  • Identify and evaluate regulatory CMC risks and develop mitigation strategies to support compliant and timely execution of site and development activities.
  • Contribute to regulatory submissions and health authority interactions for products manufactured or planned to be manufactured at Sanford, including assessing CMC information, responding to regulatory questions, and performing other required activities.
  • Shape regulatory CMC input into site and product lifecycle planning, including assessing regulatory implications associated with manufacturing strategy, process changes, product introductions, and other business or development initiatives.
  • Support Sanford regulatory inspection readiness and execution, including preparing for inspections, participating in inspection activities, and developing responses and remediation plans related to CMC matters.
  • Monitor and coordinate regulatory commitments and CMC actions associated with Sanford activities, working with stakeholders to support timely and compliant completion.
  • Contribute to broader GRA-CMC post-approval maintenance activities and portfolio priorities, adapting support as business needs, regulatory requirements, and development priorities evolve.
Desired Qualifications
  • Exposure to regulatory activities in other major markets, such as the EU, UK, and rest of world.
  • Hands-on involvement in the preparation, submission, or maintenance of Type V DMFs or other CMC regulatory dossiers.
  • Familiarity with electronic regulatory submission and document management systems and other tools used to prepare, track, and maintain regulatory documentation.

About the company

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for its PreCheck Pilot Program on June 30, 2026.
  • Kyowa Kirin signed a U.S. access deal August 31, 2026, deferring Section 232 tariffs.
  • Pipeline remains active: KHK4951, OTL-203, and ziftomenib all advanced in 2026.

What critics are saying

  • Rocatinlimab died March 3, 2026 after Kaposi's sarcoma signals and trial termination.
  • Kyowa Kirin faces patent cliffs: major products lose protection in 2032 and 2033.
  • Sanford's $530 million build concentrates execution risk until FDA-ready production starts in 2027.

What makes Kyowa Kirin unique

  • Kyowa Kirin owns antibody, fermentation, and rare-disease manufacturing expertise since 1949.
  • The Sanford, North Carolina plant becomes its first U.S. biologics site, operational 2027.
  • Ziftomenib outside the U.S. gives Kyowa Kirin global AML rights through 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Hybrid Work Options
  • Pet Insurance

Growth & Insights and Company News

6 month growth

-2%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

PR Newswire
Dec 15th, 2025
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors

/PRNewswire/ -- Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A...

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding